Narayana Nethralaya Eye Institute, Bangalore, India.
GM Eye Institute, Raipur, India.
Asia Pac J Ophthalmol (Phila). 2021 Aug 27;10(5):437-441. doi: 10.1097/APO.0000000000000388.
Retinopathy of prematurity (ROP) is the leading cause of preventable infant blindness in the world. India leads all nations with the highest number of premature infants born each year. Asia has the highest estimated incidence, where visual loss from ROP is over twice as high per million live births compared to established market economies. The problems of ROP management in these countries are compounded by a large cohort of babies who require screening, relatively few ROP specialists, and more recently medico-legal challenges. The authors share the Indian jurisprudence literature from the past decade relating to ROP, summarizing key clinical lessons learned from these legal judgments. The authors endeavor to enlist good clinical practices for various key steps involved in ROP care to help mitigate future litigations as well as protect the clinical interest of the infants who require ROP screening and treatment.
早产儿视网膜病变（ROP）是全球可预防的婴幼儿盲的主要原因。印度每年早产儿的出生数量位居世界第一。亚洲 ROP 的发病率估计最高，每百万例活产中因 ROP 导致的视力丧失是发达市场经济体的两倍多。ROP 管理方面的问题因大批需要筛查的婴儿、相对较少的 ROP 专家以及最近的医疗法律挑战而更加复杂。作者分享了过去十年中与 ROP 相关的印度判例法文献，总结了从这些法律判决中获得的关键临床经验教训。作者努力制定 ROP 护理各个关键步骤的良好临床实践，以帮助减轻未来的诉讼，并保护需要 ROP 筛查和治疗的婴儿的临床利益。
